Call to action: a five nations consensus on the use of intravenous zoledronate after hip fracture.

"Declaration of Conflicts of Interest All eight authors have completed and submitted the declaration of interest forms used by NICE for its advisory committees. These identify that M.K.J. is an advisory group member, that O.S. and M.K.J. have received speaker fees, that M.K.J. has received institutional grant funding, and consultancy fees and that A.J.B. and M.K.J. have received support for conference registration, accommodation and travel from various drug companies. However, none of these companies are the manufacturers of Aclasta or of generic forms of zoledronate. The authors’ other declarations, of non-financial, professional or personal interest reflect their voluntary roles in the national and international organisation that are described in the Methodology section; including A.J., A.M. and E.A.’s roles as leads of the hip fracture audits for the five nations of the British Isles. Declaration of Sources of Funding None."

"Declaration of Sources of Funding None."